MONTRÉAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced that Jean-Paul Castaigne, MD, President and CEO of Angiochem is scheduled to present a company overview at the Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel in Boston, MA on Thursday, September 16th at 4:25p.m. EDT.
